ATE552257T1 - Positive allosterische chinolizidinon-m1- rezeptormodulatoren - Google Patents
Positive allosterische chinolizidinon-m1- rezeptormodulatorenInfo
- Publication number
- ATE552257T1 ATE552257T1 AT08839786T AT08839786T ATE552257T1 AT E552257 T1 ATE552257 T1 AT E552257T1 AT 08839786 T AT08839786 T AT 08839786T AT 08839786 T AT08839786 T AT 08839786T AT E552257 T1 ATE552257 T1 AT E552257T1
- Authority
- AT
- Austria
- Prior art keywords
- positive allosteric
- quinolicidinone
- receptor modulators
- receptor
- compounds
- Prior art date
Links
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- 102000017927 CHRM1 Human genes 0.000 abstract 3
- 101150073075 Chrm1 gene Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99942407P | 2007-10-18 | 2007-10-18 | |
| PCT/US2008/011752 WO2009051715A1 (en) | 2007-10-18 | 2008-10-15 | Quinolizidinone m1 receptor positive allosteric modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE552257T1 true ATE552257T1 (de) | 2012-04-15 |
Family
ID=40229870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08839786T ATE552257T1 (de) | 2007-10-18 | 2008-10-15 | Positive allosterische chinolizidinon-m1- rezeptormodulatoren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8258135B2 (de) |
| EP (1) | EP2212322B1 (de) |
| JP (1) | JP2011500678A (de) |
| AT (1) | ATE552257T1 (de) |
| AU (1) | AU2008311971A1 (de) |
| CA (1) | CA2700648A1 (de) |
| WO (1) | WO2009051715A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2252151B1 (de) * | 2008-02-13 | 2014-05-14 | Merck Sharp & Dohme Corp. | Positive allosterische chinolizidinon-m1-rezeptormodulatoren |
| EP2575454B1 (de) * | 2010-05-28 | 2018-08-29 | Merck Sharp & Dohme Corp. | Positive allostere naphthalen-carboxamid-m1-rezeptormodulatoren |
| WO2013129622A1 (ja) | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP2921480B1 (de) | 2012-11-19 | 2017-10-11 | Takeda Pharmaceutical Company Limited | Stickstoffhaltige heterocyclische verbindung |
| PT3802517T (pt) | 2018-06-07 | 2023-03-20 | Idorsia Pharmaceuticals Ltd | Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose |
| AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| CN111116576A (zh) * | 2019-12-01 | 2020-05-08 | 北京师范大学 | 一种喹嗪酮类化合物及其制备方法 |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869500A (en) * | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| WO2006033422A1 (ja) * | 2004-09-21 | 2006-03-30 | Japan Tobacco Inc. | キノリジノン化合物、およびそのhivインテグラーゼ阻害剤としての利用 |
| EP2252151B1 (de) * | 2008-02-13 | 2014-05-14 | Merck Sharp & Dohme Corp. | Positive allosterische chinolizidinon-m1-rezeptormodulatoren |
-
2008
- 2008-10-15 EP EP08839786A patent/EP2212322B1/de not_active Not-in-force
- 2008-10-15 WO PCT/US2008/011752 patent/WO2009051715A1/en not_active Ceased
- 2008-10-15 AU AU2008311971A patent/AU2008311971A1/en not_active Abandoned
- 2008-10-15 AT AT08839786T patent/ATE552257T1/de active
- 2008-10-15 CA CA2700648A patent/CA2700648A1/en not_active Abandoned
- 2008-10-15 JP JP2010529934A patent/JP2011500678A/ja not_active Withdrawn
- 2008-10-15 US US12/738,208 patent/US8258135B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2212322B1 (de) | 2012-04-04 |
| WO2009051715A1 (en) | 2009-04-23 |
| CA2700648A1 (en) | 2009-04-23 |
| AU2008311971A1 (en) | 2009-04-23 |
| JP2011500678A (ja) | 2011-01-06 |
| US20100222355A1 (en) | 2010-09-02 |
| EP2212322A1 (de) | 2010-08-04 |
| US8258135B2 (en) | 2012-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2011000209A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
| MX2012002583A (es) | Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1. | |
| EP2582676A4 (de) | Positive allosterische tetrahydrochinolin-amid-m1-rezeptormodulatoren | |
| ATE475650T1 (de) | Positive allosterische chinolon-m1- rezeptormodulatoren | |
| MX367623B (es) | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. | |
| EA201171197A1 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| MY153979A (en) | Substituted piperidino-dihydrothienopyrimidine | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| IN2014KN01075A (de) | ||
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| WO2009117283A3 (en) | Quinolizidinone m1 receptor positive allosteric modulators | |
| CY1116158T1 (el) | Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| WO2009134668A3 (en) | 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators | |
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
| EP2073635A4 (de) | Makrozyklische spiropiperidin-beta-sekretase-hemmer zur behandlung von morbus alzheimer | |
| MX2013002295A (es) | 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| ATE477820T1 (de) | Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten | |
| JO2919B1 (en) | Aryl methyl benzocoinazolinone M1 positive allosteric modulation receptor |